Zydus wins DCGI nod to launch Phase III trials of new anti-malarial drug Zintrodiazine
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
